Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Retained Earnings (2022 - 2025)

BioXcel Therapeutics has reported Retained Earnings over the past 4 years, most recently at -$720.1 million for Q4 2025.

  • Quarterly results put Retained Earnings at -$720.1 million for Q4 2025, down 10.75% from a year ago — trailing twelve months through Dec 2025 was -$720.1 million (down 10.75% YoY), and the annual figure for FY2025 was -$720.1 million, down 10.75%.
  • Retained Earnings for Q4 2025 was -$720.1 million at BioXcel Therapeutics, down from -$707.5 million in the prior quarter.
  • Over the last five years, Retained Earnings for BTAI hit a ceiling of -$277.3 million in Q1 2022 and a floor of -$720.1 million in Q4 2025.
  • Median Retained Earnings over the past 4 years was -$604.0 million (2023), compared with a mean of -$549.7 million.
  • Biggest five-year swings in Retained Earnings: tumbled 67.47% in 2023 and later decreased 6.49% in 2025.
  • BioXcel Therapeutics' Retained Earnings stood at -$411.5 million in 2022, then crashed by 43.51% to -$590.6 million in 2023, then dropped by 10.09% to -$650.2 million in 2024, then fell by 10.75% to -$720.1 million in 2025.
  • The last three reported values for Retained Earnings were -$720.1 million (Q4 2025), -$707.5 million (Q3 2025), and -$676.6 million (Q2 2025) per Business Quant data.